The Harvard/Boston City ACTU has four clinical centers for trials of promising drugs or drug combinations in the treatment of HIV-infection or its complications. The four centers are the Massachusetts General Hospital (MGH), Beth Israel Hospital (BIH), New England Deaconess Hospital (NEDH) and Boston City Hospital (BCH). This collaborative group draws from a wide patient catchment area in Massachusetts and throughout New England, including all socio-economic groups. Both sexes are represented and there is a wide diversity of racial and ethnic groups included in these studies. All adult risk groups participate, and the numbers of under-represented and minority population participants has risen steadily over recent years. Studies are conducted of anti-retrovirals, as well as of agents active against opportunistic pathogens, cancers, and metabolic or neurologic complications of HIV infection. Both Phase I and Phase II-III studies are performed. The current proposal is to expand these studies and to broaden the net of underrepresented populations included in clinical trials. Plans are described to continue expansion of studies into these groups. Harvard/Boston City is also applying to be a Center for Protocol Mandated Virology (Subproject 9002) and a Center for Developmental Research in Virology (Subproject #1). Our group has made major contributions to existing knowledge concerning HIV-1 and its role in AIDS, including the initial isolation of HIV-1 from genital secretions, monocyte-macrophages, and the central nervous system. Harvard has participated in the ACTG guality control program since its inception, and is conducting critical studies on viral resistance and quantitation. Plans are to expand our research programs on drug resistance of HIV-1, herpes simplex, and cytomegalovirus, as well as on PCR-based technology for HIV-1 quantitation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027659-07
Application #
3547366
Study Section
Special Emphasis Panel (SRC (35))
Project Start
1992-04-01
Project End
1996-01-31
Budget Start
1993-02-01
Budget End
1994-01-31
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Bisson, Gregory P; Ramchandani, Ritesh; Miyahara, Sachiko et al. (2017) Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS 31:2217-2225
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6
Erlandson, Kristine M; Kitch, Douglas; Tierney, Camlin et al. (2013) Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS 27:2069-79
Gandhi, Rajesh T; Bosch, Ronald J; Aga, Evgenia et al. (2013) Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther 18:607-13
Taiwo, Babafemi; Acosta, Edward P; Ryscavage, Patrick et al. (2013) Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 64:167-73
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Chang, J Judy; Woods, Matt; Lindsay, Robert J et al. (2013) Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 208:830-8
Robbins, Gregory K; Testa, Marcia A; Su, Max et al. (2013) Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384. HIV Clin Trials 14:235-53
Sacktor, N; Miyahara, S; Deng, L et al. (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 77:1135-42
Bhattacharya, Debika; Umbleja, T; Carrat, F et al. (2010) Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 55:170-5

Showing the most recent 10 out of 88 publications